PDF(Pubmed)
Abstract：
UNASSIGNED: The endocannabinoid system (ECS), discovered in the 1990s, is a system involved with maintaining cellular homeostasis by down-regulating the damaging inflammatory responses and upregulating regenerative processes. Cannabidiol (CBD), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV) are all phytocannabinoids found in varying quantities in hemp extract. These three cannabinoids have novel therapeutic effects on hair regrowth through the ECS. The method of action is different from and synergistic with current hair regrowth therapies. The three cannabinoids are fat-soluble and poorly absorbed past the epidermis, but topical application easily reaches hair follicles where they act as partial or full CB1 antagonist and agonist of transient receptor potential vanilloid-1 (TRPV1) and vanilloid receptor-4 (TRPV4). All these ECS receptors relate to hair follicle function. Blocking the CB1 receptor on the hair follicle has been shown to result in hair shaft elongation; in addition, the hair follicle cycle (anagen, catagen, and telogen phases) is controlled by TRPV1. The effects of CBD on hair growth are dose dependent and higher doses may result in premature entry into the catagen phase through a different receptor known as TRPV4. CBD has also been shown to increase Wnt signaling, which causes dermal progenitor cells to differentiate into new hair follicles and maintains anagen phase of the hair cycle.
UNASSIGNED: This study was conducted on subjects with androgenetic alopecia (AGA), as follow-up to a prior published study using hemp extract high in CBD without CBDV or THCV. That study showed an average 93.5% increase in hair numbers after 6 months of use. This subsequent study is being done to determine if daily topical application of a hemp-oil high in CBD, THCV, and CBDV concentrations would result in improved hair regrowth in the area of the scalp most affected by AGA.
UNASSIGNED: A case series study was done of 31 (15 men and 16 women, 27 Caucasian, 2 Asian, and 1 mixed race) subjects with AGA. They used a once-daily topical hemp extract formulation, averaging about 33 mg/day for 6 months. A hair count of the greatest area of alopecia was carried out before treatment was started and again after 6 months of treatment. To facilitate consistent hair count analysis, a permanent tattoo was placed at the point for maximum hair loss on the scalp. The subjects were also asked to qualitatively rate their psychosocial perception of \"scalp coverage\" improvement after the study was completed. The qualitative scale included \"very unhappy,\" \"unhappy,\" \"neutral,\" \"happy,\" and \"very happy.\" The subjects were photographed in a standard manner before and after the study. The photographs were compared for improvements in \"scalp coverage\" by an independent physician. The qualitative scale included \"none,\" \"mild,\" \"moderate,\" and \"extensive\" improvement of scalp coverage.
UNASSIGNED: The results revealed that all subjects had some regrowth. This ranged from 31.25% (from 16 to 21 hairs) to 2000% (from 1 to 21 hairs). The average increase was statistically significant 246% (15.07 hairs/cm2 increase) in men and 127% (16.06 hairs/cm2) in women. There were no reported adverse effects. All subjects rated their psychosocial perception of the effects of the hair loss, as \"happy\" or \"very happy.\" Independent review of the photographs revealed evidence of \"mild\" to \"extensive\" scalp coverage improvements for all of the subjects.
UNASSIGNED: Although the exact mechanism of therapeutic effects is not known, THCV and CBDV are most likely functioning as full CB1 receptor neutral antagonists and CBD is most likely functioning as a partial CB1 receptor antagonist and potentially through Wnt messaging. All three cannabinoids were functioning as TRPV1 agonists. The addition of menthol through the peppermint extract is probably acting through promoting a rapid onset of anagen phase. This topical hemp formulation was superior to oral finasteride, 5% minoxidil once daily foam and CBD topical extract alone. Since this hemp extract works through novel mechanisms entirely different from both finasteride and minoxidil, it can be used in conjunction with these current drugs and would be expected to have synergistic effects. However, safety and efficacy of this combination would be to be evaluated.
UNASSIGNED: This study was conducted on subjects with androgenetic alopecia (AGA), as follow-up to a prior published study using hemp extract high in CBD without CBDV or THCV. That study showed an average 93.5% increase in hair numbers after 6 months of use. This subsequent study is being done to determine if daily topical application of a hemp-oil high in CBD, THCV, and CBDV concentrations would result in improved hair regrowth in the area of the scalp most affected by AGA.
UNASSIGNED: A case series study was done of 31 (15 men and 16 women, 27 Caucasian, 2 Asian, and 1 mixed race) subjects with AGA. They used a once-daily topical hemp extract formulation, averaging about 33 mg/day for 6 months. A hair count of the greatest area of alopecia was carried out before treatment was started and again after 6 months of treatment. To facilitate consistent hair count analysis, a permanent tattoo was placed at the point for maximum hair loss on the scalp. The subjects were also asked to qualitatively rate their psychosocial perception of \"scalp coverage\" improvement after the study was completed. The qualitative scale included \"very unhappy,\" \"unhappy,\" \"neutral,\" \"happy,\" and \"very happy.\" The subjects were photographed in a standard manner before and after the study. The photographs were compared for improvements in \"scalp coverage\" by an independent physician. The qualitative scale included \"none,\" \"mild,\" \"moderate,\" and \"extensive\" improvement of scalp coverage.
UNASSIGNED: The results revealed that all subjects had some regrowth. This ranged from 31.25% (from 16 to 21 hairs) to 2000% (from 1 to 21 hairs). The average increase was statistically significant 246% (15.07 hairs/cm2 increase) in men and 127% (16.06 hairs/cm2) in women. There were no reported adverse effects. All subjects rated their psychosocial perception of the effects of the hair loss, as \"happy\" or \"very happy.\" Independent review of the photographs revealed evidence of \"mild\" to \"extensive\" scalp coverage improvements for all of the subjects.
UNASSIGNED: Although the exact mechanism of therapeutic effects is not known, THCV and CBDV are most likely functioning as full CB1 receptor neutral antagonists and CBD is most likely functioning as a partial CB1 receptor antagonist and potentially through Wnt messaging. All three cannabinoids were functioning as TRPV1 agonists. The addition of menthol through the peppermint extract is probably acting through promoting a rapid onset of anagen phase. This topical hemp formulation was superior to oral finasteride, 5% minoxidil once daily foam and CBD topical extract alone. Since this hemp extract works through novel mechanisms entirely different from both finasteride and minoxidil, it can be used in conjunction with these current drugs and would be expected to have synergistic effects. However, safety and efficacy of this combination would be to be evaluated.
摘要：
■内源性大麻素系统（ECS），在1990年代发现的，是通过下调破坏性炎症反应和上调再生过程来维持细胞稳态的系统。大麻二酚（CBD），四氢大麻酚(THCV),大麻素和大麻素（CBDV）都是在大麻提取物中以不同数量发现的植物大麻素。这三种大麻素对通过ECS的毛发再生具有新的治疗作用。作用方法不同于目前的毛发再生疗法并且与之协同。这三种大麻素是脂溶性的，通过表皮吸收不良，但是局部应用很容易到达毛囊，在那里它们充当部分或全部CB1拮抗剂和瞬时受体电位香草素1（TRPV1）和香草素受体4（TRPV4）的激动剂。所有这些ECS受体都与毛囊功能有关。阻断毛囊上的CB1受体已被证明会导致毛干伸长；此外，毛囊周期(生长期，capagen,和端粒相）由TRPV1控制。CBD对毛发生长的影响是剂量依赖性的,并且较高的剂量可能导致通过称为TRPV4的不同受体过早进入分解期。CBD也被证明增加Wnt信号，这导致真皮祖细胞分化成新的毛囊并维持毛发周期的生长期。
■这项研究是针对雄激素性脱发（AGA）的受试者进行的，作为先前发表的研究的后续研究，该研究使用大麻提取物高CBD而不含CBDV或THCV。该研究表明，使用6个月后，头发数量平均增加了93.5％。这项后续研究正在进行，以确定是否每天局部应用高CBD的大麻油，THCV,和CBDV浓度将导致受AGA影响最大的头皮区域的毛发再生改善。
■对31名（15名男性和16名女性，27白种人，2亚洲人,和1个混合种族）与AGA。他们使用了每日一次的外用大麻提取物配方，平均约33毫克/天，持续6个月。在治疗开始之前和治疗6个月后再次进行脱发的最大区域的毛发计数。为了促进一致的毛发计数分析，永久纹身被放置在头皮上最大的脱发点。研究完成后，受试者还被要求对他们对“头皮覆盖率”改善的心理社会感知进行定性评价。定性量表包括“非常不开心，\"\"不开心,\"\"中性,\"\"快乐,\"和\"很高兴。“受试者在研究前后以标准方式拍照。由独立医生比较了这些照片在“头皮覆盖率”方面的改善情况。定性量表包括“没有，\"\"温和，“”适度，“和”头皮覆盖率的广泛改善。
■结果显示所有受试者都有一些再生。这个范围从31.25%(从16到21根毛发)到2000%(从1到21根毛发)。男性平均增幅为246%(15.07根头发/cm2增幅),女性为127%(16.06根头发/cm2增幅)。没有报告的不良反应。所有受试者都评估了他们对脱发影响的心理社会感知，作为“快乐”或“非常快乐”。“对照片的独立审查显示，所有受试者的头皮覆盖率都得到了“轻度”到“广泛”的改善。
■尽管治疗效果的确切机制尚不清楚，THCV和CBDV最有可能作为完全CB1受体中性拮抗剂起作用,并且CBD最有可能作为部分CB1受体拮抗剂起作用并且潜在地通过Wnt消息传递起作用。所有三种大麻素都起TRPV1激动剂的作用。通过薄荷提取物添加薄荷醇可能通过促进生长期阶段的快速开始起作用。这种外用大麻制剂优于口服非那雄胺，5％米诺地尔每日一次泡沫和CBD局部提取物单独。由于这种大麻提取物通过与非那雄胺和米诺地尔完全不同的新机制起作用，它可以与这些目前的药物联合使用，并有望产生协同作用。然而,该组合的安全性和有效性有待评估.
■这项研究是针对雄激素性脱发（AGA）的受试者进行的，作为先前发表的研究的后续研究，该研究使用大麻提取物高CBD而不含CBDV或THCV。该研究表明，使用6个月后，头发数量平均增加了93.5％。这项后续研究正在进行，以确定是否每天局部应用高CBD的大麻油，THCV,和CBDV浓度将导致受AGA影响最大的头皮区域的毛发再生改善。
■对31名（15名男性和16名女性，27白种人，2亚洲人,和1个混合种族）与AGA。他们使用了每日一次的外用大麻提取物配方，平均约33毫克/天，持续6个月。在治疗开始之前和治疗6个月后再次进行脱发的最大区域的毛发计数。为了促进一致的毛发计数分析，永久纹身被放置在头皮上最大的脱发点。研究完成后，受试者还被要求对他们对“头皮覆盖率”改善的心理社会感知进行定性评价。定性量表包括“非常不开心，\"\"不开心,\"\"中性,\"\"快乐,\"和\"很高兴。“受试者在研究前后以标准方式拍照。由独立医生比较了这些照片在“头皮覆盖率”方面的改善情况。定性量表包括“没有，\"\"温和，“”适度，“和”头皮覆盖率的广泛改善。
■结果显示所有受试者都有一些再生。这个范围从31.25%(从16到21根毛发)到2000%(从1到21根毛发)。男性平均增幅为246%(15.07根头发/cm2增幅),女性为127%(16.06根头发/cm2增幅)。没有报告的不良反应。所有受试者都评估了他们对脱发影响的心理社会感知，作为“快乐”或“非常快乐”。“对照片的独立审查显示，所有受试者的头皮覆盖率都得到了“轻度”到“广泛”的改善。
■尽管治疗效果的确切机制尚不清楚，THCV和CBDV最有可能作为完全CB1受体中性拮抗剂起作用,并且CBD最有可能作为部分CB1受体拮抗剂起作用并且潜在地通过Wnt消息传递起作用。所有三种大麻素都起TRPV1激动剂的作用。通过薄荷提取物添加薄荷醇可能通过促进生长期阶段的快速开始起作用。这种外用大麻制剂优于口服非那雄胺，5％米诺地尔每日一次泡沫和CBD局部提取物单独。由于这种大麻提取物通过与非那雄胺和米诺地尔完全不同的新机制起作用，它可以与这些目前的药物联合使用，并有望产生协同作用。然而,该组合的安全性和有效性有待评估.
